Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine October 2006, 47 (10) 9a-10a;
  • Article
  • Info & Metrics
  • PDF
Loading

Late effects of radioablation: Reiners and colleagues review recent literature on the risk of secondary cancers after radiation treatment and preview an article in this issue of JNM on potential sequelae to radioiodine ablation in children near Chernobyl.
Page 1563

Optimal patient selection for CRT: Ypenburg and colleagues assess whether the extent of myocardial viability on 18F-FDG SPECT at intervention can accurately forecast the success of cardiac resynchronization therapy in patients with heart failure.
Page 1565

Enhanced imaging of granulomas: Nishiyama and colleagues compare tracer uptake on 18F-FDG PET and 67Ga whole-body planar and thoracic imaging in the evaluation of pulmonary and extrapulmonary involvement in patients with sarcoidosis.
Page 1571

Figure

Strategic approach to heel pain: Frater and colleagues devise a set of scintigraphic criteria based on blood-pool abnormalities to predict the success of steroid injection therapies in patients with plantar fasciitis.
Page 1577

Noninvasive misery perfusion evaluation: Kobayashi and colleagues describe a novel technique for measuring asymmetric increases in oxygen extraction fraction in H215O PET studies in cerebrovascular disease and point to advantages in technical simplicity and decreased patient discomfort.
Page 1581

Reevaluating 131I doses in the elderly: Tuttle and colleagues look at age-associated differences in maximum tolerated activity in fixed-dose 131I therapy for metastatic thyroid cancer.
Page 1587

PET and bone marrow cellularity: Agool and colleagues investigate the feasibility of using 18F-FLT PET to visualize and quantify proliferative activity in the bone marrow compartment to differentiate among various hematologic disorders.
Page 1592

Figure

Identifying somatostatin receptor subtypes: van Essen and colleagues describe the effects of 177Lu-octreotate therapy in patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas, and melanomas.
Page 1599

Figure

Brain PET and operable NSCLC: Posther and colleagues ask whether 18F-FDG PET provides useful information in patients whose suspected or proven non–small cell lung cancer is considered resectable on the basis of conventional imaging approaches.
Page 1607

Kinetics of 18F-FLT brain imaging: Muzi and colleagues investigate compartmental modeling of tracer transport and retention in 18F-FLT studies to assess cellular proliferation in patients with gliomas.
Page 1612

Figure

PET and celiac disease progression: Hadithi and colleagues compare 18F-FDG PET and CT in the detection of enteropathy-associated T-cell lymphoma in patients with refractory celiac disease.
Page 1622

Figure

PET/CT vs. CT in thymic tumors: Sung and colleagues assess the utility of 18F-FDG PET/CT in distinguishing subgroups of thymic epithelial tumors and for staging extent of disease.
Page 1628

PET/CT in SNS imaging: Franzius and colleagues evaluate the feasibility of whole-body 11C-HED PET/low-dose CT for examination of tumors of the sympathetic nervous system and compare the results with those from 123I-MIBG scintigraphy and SPECT/CT.
Page 1635

Effective PET/CT dose reduction: Rodríguez-Vigil and colleagues compare contrast-enhanced full-dose PET/CT and unenhanced low-dose 18F-FDG PET/CT in lesion detection and initial staging of Hodgkin's disease and non-Hodgkin's lymphoma.
Page 1643

Figure

Novel tracer for prostate imaging: Peng and colleagues investigate the use of 64CuCl2 as a probe in PET localization of human prostate cancer xenografts in mice and discuss the implications for clinical use in locally recurrent tumors.
Page 1649

Figure

Radiologic threat preparedness: Barnett and colleagues provide an educational overview of radiologic and nuclear terrorism as public health threats and discuss appropriate preparedness and response perspectives for nuclear medicine professionals.
Page 1653

Optimizing clinical SPECT: Xiao and colleagues compare the performances of Monte Carlo–based and window-based scatter correction in 99mTc SPECT cardiac imaging.
Page 1662

Molecular targeting of mRNA: Watanabe and colleagues investigate the therapeutic effect of Auger electrons emitted by 111In-labeled phosphorothioate antisense oligonucleotides on human neuroblastoma cells.
Page 1670

ImmunoPET investigations: McBride and colleagues continue their work with bispecific antibody pretargeting for tumor imaging, here reporting on a radioiodination procedure to assess PET imaging with 124I.
Page 1678

Figure

Tracing dependence: Horti and colleagues evaluate an 11C-labeled analog of a cerebral cannabinoid receptor antagonist as a potential radioligand for PET imaging of addiction and related neuropsychiatric disorders.
Page 1689

Novel serotonin agent: Saigal and colleagues report on the radiosynthesis and in vitro and in vivo binding characteristics of 18F-mefway, a more stable serotonin 5-HT1A agent for use in PET imaging in disorders of the central nervous system.
Page 1697

99mTc-labeled fibronectin antibodies: Berndorff and colleagues detail the synthesis and 99mTc labeling of compounds to target the angiogenesis-associated extracellular matrix protein ED-B fibronectin for scintigraphic molecular imaging of solid tumors.
Page 1707

Figure

DNA synthesis imaging: Toyohara and colleagues describe the production of a novel thymidine analog for simplified 11C-PET imaging of DNA synthesis in tumor cell proliferation.
Page 1717

Long-term follow-up recommended: Travis and Stabin review treatment data from children in the Chernobyl area who underwent radioiodine ablation and estimate the increased risk of cancers––including breast cancer––in this population.
Page 1723

ON THE COVER

Because serotonin 5-HT1A receptors have been implicated in disorders of the central nervous system, efforts are under way to develop fluorinated PET radiotracers that are stable to metabolism, easily synthesized, and highly selective for 5-HT1A receptors. 18F-Mefway has shown value as such a radiotracer and is, in addition, sensitive to being displaced by serotonin, suggesting potential as a PET agent for measuring changes in serotonin concentration in the living brain.

Figure

SEE PAGE 1703

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 47 (10)
Journal of Nuclear Medicine
Vol. 47, Issue 10
October 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Oct 2006, 47 (10) 9a-10a;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Oct 2006, 47 (10) 9a-10a;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • A Perspective on Post-Chernobyl Radioablation in Young Females
  • Extent of Viability to Predict Response to Cardiac Resynchronization Therapy in Ischemic Heart Failure Patients
  • Comparative Evaluation of 18F-FDG PET and 67Ga Scintigraphy in Patients with Sarcoidosis
  • Bone Scintigraphy Predicts Outcome of Steroid Injection for Plantar Fasciitis
  • Diagnosis of Misery Perfusion Using Noninvasive 15O-Gas PET
  • Empiric Radioactive Iodine Dosing Regimens Frequently Exceed Maximum Tolerated Activity Levels in Elderly Patients with Thyroid Cancer
  • 18F-FLT PET in Hematologic Disorders: A Novel Technique to Analyze the Bone Marrow Compartment
  • Effects of Therapy with [177Lu-DOTA0, Tyr3]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma
  • Yield of Brain 18F-FDG PET in Evaluating Patients with Potentially Operable Non–Small Cell Lung Cancer
  • Kinetic Analysis of 3′-Deoxy-3′-18F-Fluorothymidine in Patients with Gliomas
  • 18F-FDG PET Versus CT for the Detection of Enteropathy-Associated T-Cell Lymphoma in Refractory Celiac Disease
  • 18F-FDG PET/CT of Thymic Epithelial Tumors: Usefulness for Distinguishing and Staging Tumor Subgroups
  • Whole-Body PET/CT with 11C-Meta-Hydroxyephedrine in Tumors of the Sympathetic Nervous System: Feasibility Study and Comparison with 123I-MIBG SPECT/CT
  • PET/CT in Lymphoma: Prospective Study of Enhanced Full-Dose PET/CT Versus Unenhanced Low-Dose PET/CT
  • PET of Human Prostate Cancer Xenografts in Mice with Increased Uptake of 64CuCl2
  • Understanding Radiologic and Nuclear Terrorism as Public Health Threats: Preparedness and Response Perspectives
  • Evaluation of 3D Monte Carlo–Based Scatter Correction for 99mTc Cardiac Perfusion SPECT
  • Molecular Therapy of Human Neuroblastoma Cells Using Auger Electrons of 111In-Labeled N-myc Antisense Oligonucleotides
  • Bispecific Antibody Pretargeting PET (ImmunoPET) with an 124I-Labeled Hapten-Peptide
  • 11C-JHU75528: A Radiotracer for PET Imaging of CB1 Cannabinoid Receptors
  • Synthesis and Biologic Evaluation of a Novel Serotonin 5-HT1A Receptor Radioligand, 18F-Labeled Mefway, in Rodents and Imaging by PET in a Nonhuman Primate
  • Imaging of Tumor Angiogenesis Using 99mTc-Labeled Human Recombinant Anti-ED-B Fibronectin Antibody Fragments
  • Evaluation of 4′-[Methyl-14C]Thiothymidine for In Vivo DNA Synthesis Imaging
  • 131I Ablation Treatment in Young Females After the Chernobyl Accident
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire